Back to all studies
RecruitingNCT07105111

Effectiveness of valbenazine in adults with tardive dyskinesia

The registry lists this study as recruiting. Study locations are listed in the United States. Confirm recruitment at each site. It focuses on adults with tardive dyskinesia who remain symptomatic while receiving or after stopping a VMAT2 inhibitor.

Schizophrenia, Depression, ...DrugOver 18 Years
In plain English

Key information made simple

What is this study testing?

This study is testing whether Valbenazine may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive Valbenazine, attend study visits with the research team. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: August 29, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
50
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT07105111
Official title
A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 22 sites
  • Neurocrine Clinical Site
    Bryant, Arkansas
    Site status: Recruiting
  • Neurocrine Clinical Site
    Chino, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    Fountain Valley, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    Fresno, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    Long Beach, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    Orange, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    Redlands, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    San Diego, California
    Site status: Recruiting
  • Neurocrine Clinical Site
    Bonita Springs, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Hialeah, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Miami, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Miami, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Orange City, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Port Charlotte, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Tampa, Florida
    Site status: Recruiting
  • Neurocrine Clinical Site
    Augusta, Georgia
    Site status: Recruiting
  • Neurocrine Clinical Site
    Marietta, Georgia
    Site status: Recruiting
  • Neurocrine Clinical Site
    Naperville, Illinois
    Site status: Recruiting
  • Neurocrine Clinical Site
    Omaha, Nebraska
    Site status: Recruiting
  • Neurocrine Clinical Site
    Independence, Ohio
    Site status: Recruiting
  • Neurocrine Clinical Site
    Austin, Texas
    Site status: Recruiting
  • Neurocrine Clinical Site
    Richmond, Virginia
    Site status: Recruiting

Want help reviewing this study?

Loading the security check...
Study ID: NCT07105111. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Valbenazine. Phase 4 studies usually happen after treatment approval, to monitor real-world use.

Who might this study be for?

This study may concern people with schizophrenia; age range: Over 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

Will I need to change, stop, or stabilize my current treatment?

The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Neurocrine Biosciences, which appears to be a biotech company. The listed contact or investigator is Neurocrine Biosciences, affiliated with Neurocrine Biosciences. Sponsor website: https://www.neurocrine.com. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me